Terms of Use
The logos of various companies displayed on Fey.com are for editorial and informational purposes only. Fey.com is not affiliated with, sponsored by, or endorsed by these companies. All logos are trademarks of their respective owners and are used under the principles of fair use. We make no claim of ownership over these trademarks.
Restrictions on Use
While we provide these logos for individual download and personal use, any form of automated scraping or bulk downloading of logos from Fey.com is strictly prohibited. Users are permitted to download logos manually, one at a time, as intended through our user interface. Unauthorized mass retrieval or use of logos will be considered a violation of our terms and may result in restricted access or legal action. For concerns or inquiries regarding the use of any logo, please contact us at info@fey.com.
Franklin U.S. Core Dividend Tilt Index ETF - Franklin Genomic Advancements ETF is an exchange traded fund launched by Franklin Resources, Inc. The fund is managed by Franklin Advisers, Inc. It invests in public equity markets of global region. The fund invests in stocks of companies operating across extending and enhancing the quality of human and other life by incorporating technological and scientific developments, improvements and advancements in the field of genomics into their business, such as by offering new products or services that rely on genetic engineering, gene therapy, genome analysis, dna sequencing, synthesis or instrumentation sectors. It invests in growth and value stocks of companies across diversified market capitalization. It invests in stocks of companies that are deemed socially conscious in their business dealings and directly promote environmental responsibility. The fund employs fundamental analysis with bottom-up stock picking approach to create its portfolio. It employs internal and external research to create its portfolio. The fund seeks to benchmark the performance of its portfolio against the Russell 3000 Index. Franklin U.S. Core Dividend Tilt Index ETF - Franklin Genomic Advancements ETF was formed on February 25, 2020 and is domiciled in the United States.